LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Lindenwold Advisors INC

Lindenwold Advisors INC cut its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 17.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,780 shares of the medical instruments supplier’s stock after selling 575 shares during the quarter. Lindenwold Advisors INC’s holdings in LeMaitre Vascular were worth $256,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of LeMaitre Vascular in the fourth quarter worth $14,900,000. DF Dent & Co. Inc. boosted its position in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after buying an additional 53,797 shares during the period. Barclays PLC boosted its position in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after buying an additional 29,180 shares during the period. State Street Corp boosted its position in shares of LeMaitre Vascular by 3.6% in the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after buying an additional 28,525 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular by 4.5% in the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock worth $50,403,000 after buying an additional 23,443 shares during the period. 84.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Finally, Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average price target of $95.25.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Down 0.2 %

LMAT stock opened at $84.91 on Wednesday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The company has a market cap of $1.92 billion, a PE ratio of 46.40, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The business’s 50-day simple moving average is $94.90 and its 200 day simple moving average is $94.60.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. The business had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.94%. The ex-dividend date is Thursday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s payout ratio is 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.